Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
08 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-poster-presentations-on-the-study-results-of-asc30-and-asc47-at-the-85th-scientific-sessions-of-american-diabetes-association-ada-302475088.html
05 Jun 2025
// INVESTING
https://in.investing.com/news/stock-market-news/sagimet-biosciences-shares-soar-on-positive-acne-treatment-trial-results-93CH-4862187
03 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-phase-iii-trial-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-meets-all-endpoints-302472286.html
22 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-us-fda-clearance-of-ind-application-for-its-oral-small-molecule-il-17-inhibitor-asc50-for-the-treatment-of-psoriasis-302462995.html
20 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-first-participants-dosed-in-a-us-clinical-study-combining-adipose-targeted-once-monthly-injectable-small-molecule-thr-agonist-asc47-and-semaglutide-for-the-treatment-of-obesity-302460251.html
06 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-oral-and-poster-presentations-on-asc47-an-adipose-targeted-muscle-preserving-weight-loss-drug-candidate-for-obesity-at-the-32nd-european-congress-on-obesity-302446777.html
ABOUT THIS PAGE